<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00890903</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-155</org_study_id>
    <nct_id>NCT00890903</nct_id>
  </id_info>
  <brief_title>Non-Interventional Study With Vinorelbine ORAL in Advanced Non-Small Cell Lung Carcinoma(NSCLC) and Metastatic Breast Cancer (MBC)</brief_title>
  <official_title>Usage of Vinorelbin ORAL (NavelbineÂ® ORAL) in the Treatment of Advanced Non-small Cell Lung Cancer(NSCLC)and Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pierre Fabre Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pierre Fabre Pharma GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this non-interventional study is to collect data on efficacy and toxicity of
      the use of Navelbine ORAL in daily routine in Germany (especially after availability of an
      80mg capsule). The study focusses on concomitant antiemetic therapy and patient compliance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free-survival</measure>
    <time_frame>1 year after LPI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse reactions</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concomitant antiemetic therapy</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recording of combinations of applied capsules (requested by a patients' questionnaire)</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General condition of patients (requested by a patients' questionnaire)</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapy performance in the daily routine</measure>
    <time_frame>1 year after LPI</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Non Small Cell Lung Carcinoma</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>NSCLC</arm_group_label>
    <description>Patients with advanced non-small cell lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MBC</arm_group_label>
    <description>Female patients with metastatic, Anthracycline-resistent breast cancer</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with advanced non-small cell lung cancer (NSCLC) or metastatic,
        Antracycline-resistant breast cancer, treated with Navelbine capsules
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years old

          -  Male and female patients

          -  Advanced NSCLC (Stage III or IV) or Antracycline-resistant MBC

          -  Therapy with Navelbine capsules in any palliative treatment line

          -  Signed patient informed consent

        Exclusion Criteria:

          -  Pregnancy and nursing

          -  All other exclusion criteria listed in SPC (summary of product characteristics)

          -  lack of signed Patient informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pierre Fabre Pharma GmbH</name>
      <address>
        <city>Freiburg</city>
        <zip>79111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2009</study_first_submitted>
  <study_first_submitted_qc>April 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2009</study_first_posted>
  <last_update_submitted>June 28, 2012</last_update_submitted>
  <last_update_submitted_qc>June 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>non small cell lung carcinoma</keyword>
  <keyword>metastatic breast cancer</keyword>
  <keyword>MBC</keyword>
  <keyword>advanced breast cancer</keyword>
  <keyword>Navelbine</keyword>
  <keyword>Navelbine-ORAL</keyword>
  <keyword>Vinorelbine</keyword>
  <keyword>Vinorelbine-ORAL</keyword>
  <keyword>daily routine</keyword>
  <keyword>concomitant antiemetic therapy</keyword>
  <keyword>patient compliance</keyword>
  <keyword>germany</keyword>
  <keyword>non-interventional study</keyword>
  <keyword>oral anti cancer therapy</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

